Shiloh
Editor, Senior Moderator
Source: http://www.plosone.org/article/info:doi/10.1371/journal.pone.0046509
Treating and Preventing Influenza in Aged Care Facilities: A Cluster Randomised Controlled Trial
Robert Booy1, Richard I. Lindley2*, Dominic E. Dwyer3, Jiehui K. Yin1, Leon G. Heron1, Cameron R. M. Moffatt1, Clayton K. Chiu1, Alexander E. Rosewell1, Anna S. Dean1, Timothy Dobbins4, David J. Philp5, Zhanhai Gao6, C. Raina MacIntyre6
1 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney, Sydney, New South Wales, Australia, 2 Discipline of Medicine, The University of Sydney and The George Institute for Global Health, Sydney, New South Wales, Australia, 3 Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital and Sydney Institute for Emerging Infections and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia, 4 Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia, 5 School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia, 6 Faculty of Medicine, School of Public Health and Community Medicine, The University of New South Wales, Sydney, New South Wales, Australia
Influenza is an important cause of morbidity and mortality for frail older people. Whilst the antiviral drug oseltamivir (a neuraminidase inhibitor) is approved for treatment and prophylaxis of influenza during outbreaks, there have been no trials comparing treatment only (T) versus treatment and prophylaxis (T&P) in Aged Care Facilities (ACFs). Our objective was to compare a policy of T versus T&P for influenza outbreaks in ACFs...
Treating and Preventing Influenza in Aged Care Facilities: A Cluster Randomised Controlled Trial
Robert Booy1, Richard I. Lindley2*, Dominic E. Dwyer3, Jiehui K. Yin1, Leon G. Heron1, Cameron R. M. Moffatt1, Clayton K. Chiu1, Alexander E. Rosewell1, Anna S. Dean1, Timothy Dobbins4, David J. Philp5, Zhanhai Gao6, C. Raina MacIntyre6
1 National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The University of Sydney, Sydney, New South Wales, Australia, 2 Discipline of Medicine, The University of Sydney and The George Institute for Global Health, Sydney, New South Wales, Australia, 3 Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital and Sydney Institute for Emerging Infections and Biosecurity, The University of Sydney, Sydney, New South Wales, Australia, 4 Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia, 5 School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia, 6 Faculty of Medicine, School of Public Health and Community Medicine, The University of New South Wales, Sydney, New South Wales, Australia
Influenza is an important cause of morbidity and mortality for frail older people. Whilst the antiviral drug oseltamivir (a neuraminidase inhibitor) is approved for treatment and prophylaxis of influenza during outbreaks, there have been no trials comparing treatment only (T) versus treatment and prophylaxis (T&P) in Aged Care Facilities (ACFs). Our objective was to compare a policy of T versus T&P for influenza outbreaks in ACFs...